+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antisense & RNAi Therapeutics Market by Oligonucleotide Type (Antisense Oligonucleotides, Interfering RNAi), Mode Of Administration (Intrathecal, Intravenous, Oral), Therapeutic Areas, End User - Global Forecast 2025-2030- Product Image
Antisense & RNAi Therapeutics Market by Oligonucleotide Type (Antisense Oligonucleotides, Interfering RNAi), Mode Of Administration (Intrathecal, Intravenous, Oral), Therapeutic Areas, End User - Global Forecast 2025-2030- Product Image
Sale

Antisense & RNAi Therapeutics Market by Oligonucleotide Type (Antisense Oligonucleotides, Interfering RNAi), Mode Of Administration (Intrathecal, Intravenous, Oral), Therapeutic Areas, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887255
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antisense & RNAi Therapeutics Market is experiencing strong expansion driven by increasing adoption of gene-silencing modalities, advancements in delivery technologies, and strategic industry partnerships. Senior decision-makers require a comprehensive, nuanced perspective to navigate this fast-evolving sector and identify actionable opportunities.

Market Snapshot: Antisense & RNAi Therapeutics Market Overview

The Antisense & RNAi Therapeutics Market grew from USD 4.77 billion in 2024 to USD 5.48 billion in 2025. It is expected to continue growing at a CAGR of 15.20%, reaching USD 11.17 billion by 2030. This dynamic growth reflects a rising demand for gene-silencing therapies that target disease at the molecular level, supported by advancements in oligonucleotide chemistry and evolving regulatory frameworks. Strategic interests from pharma innovators, investors, and policy stakeholders are accelerating clinical development and commercialization across major regions.

Scope & Segmentation

This report comprehensively analyzes the Antisense & RNAi Therapeutics Market across modalities, administration techniques, therapeutic focus areas, end users, and geographic regions. The study addresses transformative technologies, regional adoption, and evolving business models.

  • Oligonucleotide Types: Antisense oligonucleotides, Micro interfering RNAs, Small interfering RNAs
  • Modes of Administration: Intrathecal, Intravenous, Oral, Subcutaneous, Topical
  • Therapeutic Areas: Cardiovascular, Immunology, Metabolic Disorders, Neurological Disorders, Oncology, Ophthalmology, Rare Diseases
  • End Users: Contract research organizations, Pharmaceutical companies, Research laboratories
  • Regions Covered: Americas (United States - California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the UK, France, Germany, Italy, Spain, Russia, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies Profiled: Acuitas Therapeutics Inc., Alloy Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Bayer AG, Benitec Biopharma Limited, City Therapeutics, Danaher Corporation, Eli Lilly and Company, Evox Therapeutics Ltd, GenScript Biotech Corporation, GSK PLC, Ionis Pharmaceuticals, Inc., Merck KGaA, Novo Nordisk A/S, Pfizer Inc., Ribocure Pharmaceuticals AB, Sanofi S.A., Shanghai Argo Biopharmaceutical Co., Ltd., Silence Therapeutics plc, Stoke Therapeutics, Inc., Suzhou Ribo Life Science Co., Ltd., Wave Life Sciences Ltd
  • Key Technologies Highlighted: Lipid nanoparticle carriers, locked nucleic acids, phosphorothioate modifications, AI-driven sequence design, collaboration models

Key Takeaways for Senior Decision-Makers

  • Gene-silencing therapeutics are being integrated into precision medicine strategies to address a broadening set of indications, highlighting their versatility and scalability.
  • Advances in chemical modification and delivery not only improve clinical success rates but also reduce risks related to stability and immunogenicity.
  • Stakeholder roles are shifting, with contract research organizations and academic partnerships increasingly vital to innovation pipelines.
  • Clinical pipelines are expanding beyond orphan and rare disease applications into oncology and metabolic disease, demonstrating therapeutic and commercial potential.
  • Intellectual property strategies are influencing collaboration and licensing models, impacting both technology adoption and long-term competitiveness.

Tariff Impact: Implications of U.S. 2025 Tariff Adjustments

New tariff measures enacted in the United States in 2025 have led to increased raw material and manufacturing costs in the antisense and RNAi therapeutics sector. Organizations are responding by reassessing supply chains, prioritizing domestic sourcing, and leveraging trade agreements to ensure continuity and compliance with quality standards. Regulatory agencies are considering focused tariff exemptions for critical research reagents, helping mitigate risks to development timelines and commercial launches. Strategic responses to tariff changes are influencing cost management, partnership approaches, and go-to-market strategies in the U.S. and globally.

Methodology & Data Sources

This research integrates in-depth qualitative interviews with scientists, clinicians, and executives, alongside quantitative market analytics, patent intelligence, and supply chain assessments. Peer-reviewed literature, regulatory filings, and company disclosures were triangulated through multiple validation points with subject matter experts to ensure accuracy and relevance of insights.

Why This Report Matters

  • Enables executive teams to benchmark innovation, assess investment risks, and refine strategy in the evolving gene silencing therapeutic landscape.
  • Provides actionable insights into regional trends, technology adoption, and supply chain realignment critical to long-term growth.
  • Equips leaders to anticipate regulatory, reimbursement, and sourcing shifts that influence market entry and commercial scale-up.

Conclusion

The Antisense & RNAi Therapeutics Market is at a transformational juncture, driven by scientific progress and shifting regulatory and economic factors. Informed, integrated strategies will enable stakeholders to compete effectively and realize the full potential of gene-silencing innovations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging lipid nanoparticle delivery systems enhancing siRNA stability and cellular uptake
5.2. Development of ligand conjugation platforms for targeted antisense oligonucleotide therapies
5.3. CRISPR-Cas13 mediated RNA editing integration with RNAi therapeutics for precise gene silencing
5.4. Utilization of artificial intelligence for optimized antisense sequence design and off-target prediction
5.5. Expansion of subcutaneous formulations for RNAi drugs to improve patient compliance and dosing frequency
5.6. Clinical progress in antisense therapies for rare neuromuscular disorders with high unmet medical need
5.7. Advancements in multivalent siRNA constructs targeting multiple disease pathways in oncology
5.8. Regulatory harmonization efforts accelerating global approval of novel RNAi-based therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type
8.1. Introduction
8.2. Antisense Oligonucleotides
8.3. Interfering RNAi
8.3.1. Micro Interfering RNAs
8.3.2. Small Interfering RNAs
9. Antisense & RNAi Therapeutics Market, by Mode Of Administration
9.1. Introduction
9.2. Intrathecal
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
9.6. Topical
10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas
10.1. Introduction
10.2. Cardiovascular
10.3. Immunology
10.4. Metabolic Disorders
10.5. Neurological Disorders
10.6. Oncology
10.7. Ophthalmology
10.8. Rare Diseases
11. Antisense & RNAi Therapeutics Market, by End User
11.1. Introduction
11.2. Contract Research Organizations
11.3. Pharmaceutical Companies
11.4. Research Laboratories
12. Americas Antisense & RNAi Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antisense & RNAi Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Acuitas Therapeutics Inc.
15.3.2. Alloy Therapeutics, Inc.
15.3.3. Alnylam Pharmaceuticals, Inc.
15.3.4. Arbutus Biopharma Corporation
15.3.5. Arrowhead Pharmaceuticals, Inc.
15.3.6. AstraZeneca plc
15.3.7. Bayer AG
15.3.8. Benitec Biopharma Limited
15.3.9. City Therapeutics
15.3.10. Danaher Corporation
15.3.11. Eli Lilly and Company
15.3.12. Evox Therapeutics Ltd
15.3.13. GenScript Biotech Corporation
15.3.14. GSK PLC
15.3.15. Ionis Pharmaceuticals, Inc.
15.3.16. Merck KGaA
15.3.17. Novo Nordisk A/S
15.3.18. Pfizer Inc.
15.3.19. Ribocure Pharmaceuticals AB
15.3.20. Sanofi S.A.
15.3.21. Shanghai Argo Biopharmaceutical Co., Ltd.
15.3.22. Silence Therapeutics plc
15.3.23. Stoke Therapeutics, Inc.
15.3.24. Suzhou Ribo Life Science Co., Ltd.
15.3.25. Wave Life Sciences Ltd
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTISENSE & RNAI THERAPEUTICS MARKET: RESEARCHAI
FIGURE 24. ANTISENSE & RNAI THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTISENSE & RNAI THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTISENSE & RNAI THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 81. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 82. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 83. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 84. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 85. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 88. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 89. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 94. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 95. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 98. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 112. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 134. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 136. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 144. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 145. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 146. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 147. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 150. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 151. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 154. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 155. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 156. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 157. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 160. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 161. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 164. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 165. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 166. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 167. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 170. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 171. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 176. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 177. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 180. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 181. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 184. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 185. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 186. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 187. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 190. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 191. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 206. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 210. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 214. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 216. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 220. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 224. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 225. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 226. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 227. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 230. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 231. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 234. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 235. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 236. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 237. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 240. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 244. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 245. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 246. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 247. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 250. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 251. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 254. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 255. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 256. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 257. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 260. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 261. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 264. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 265. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 266. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 267. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 270. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 271. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 274. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 275. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 276. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 277. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 280. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 281. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 284. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 285. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 286. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 287. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 290. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 291. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 294. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 295. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
TABLE 296. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2030 (USD MILLION)
TABLE 297. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 300. TURKEY ANT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antisense & RNAi Therapeutics market report include:
  • Acuitas Therapeutics Inc.
  • Alloy Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Benitec Biopharma Limited
  • City Therapeutics
  • Danaher Corporation
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Ribocure Pharmaceuticals AB
  • Sanofi S.A.
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Stoke Therapeutics, Inc.
  • Suzhou Ribo Life Science Co., Ltd.
  • Wave Life Sciences Ltd

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.17 Billion
Compound Annual Growth Rate15.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Antisense & RNAi Therapeutics Market Report 2025 - Product Image

Antisense & RNAi Therapeutics Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Antisense and RNAi Therapeutics - Global Strategic Business Report - Product Image

Antisense and RNAi Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033 - Product Image

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
Antisense & RNAi Therapeutics - A Global Market Overview - Product Image

Antisense & RNAi Therapeutics - A Global Market Overview

  • Report
  • 253 Pages
  • Global
From
Oligonucleotide Therapeutics - Global Strategic Business Report - Product Image

Oligonucleotide Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.